How has Standard BioTools ROCE changed compared to the previous year?

Return on Capital Employed (ROCE) of Standard BioTools changed from -38.67 % to -28.61 %, representing a -26.02% change. The value is higher than the previous year.

How has Standard BioTools ROCE developed historically?

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

What is the Standard BioTools ROCE?

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Standard BioTools with sector peers and the industry average to assess whether it is attractive.

How does Standard BioTools ROCE compare to the industry average?

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Standard BioTools ROCE

LAB

The Return on Capital Employed (ROCE) of Standard BioTools (LAB) as of Jul 23, 2026 is -28.61 %. In the previous year, Return on Capital Employed (ROCE) was -38.67 % — a change of -26.02% (higher).

Get this data via API

Financial Data API

ROCE

-28.61 %

YoY

-26.02%

Last updated: Jul 23, 2026

In 2026, Standard BioTools's return on capital employed (ROCE) was -28.61 %, a -26.02% increase from the -38.67 % ROCE in the previous year.

Access this data via the Eulerpool API

Docs Get Free API Key

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Standard BioTools's Return on Capital Employed (ROCE)

Standard BioTools's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Standard BioTools's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Standard BioTools's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Standard BioTools’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Standard BioTools ROCE

Standard BioTools Stock analysis

ROCE Details

Unraveling Standard BioTools's Return on Capital Employed (ROCE)

Year-to-Year Comparison

Impact on Investments

Interpreting ROCE Fluctuations

Frequently Asked Questions about Standard BioTools stock

What is the Standard BioTools ROCE 2026?

How has Standard BioTools ROCE changed compared to the previous year?

How has Standard BioTools ROCE developed historically?

What is the Standard BioTools ROCE?

What is a good ROCE?

How does Standard BioTools ROCE compare to the industry average?

Profitability — Standard BioTools

All Key Metrics — Standard BioTools

Valuation

Income Statement

Margins

Balance Sheet

Cash Flow

Profitability

Leverage

Growth

Dividend

Workforce

Quality

Other